An Act amending the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act, further providing for State Board of Pharmacy.

2025-2026 Regular Session Introduced by Lisa Baker and 9 co-sponsors

SB 1133 updates the State Board of Pharmacy’s membership makeup to reflect contemporary workforce and governance considerations.

Referred to Professional Licensure

Summary of Bill: SB 1133 (2025-2026) – Pennsylvania Pharmacy Act

Purpose and Intent

SB 1133 proposes amendments to the Pharmacy Act of 1961, with a focus on updating the composition and governance of the State Board of Pharmacy.

The primary aim appears to be updating the membership requirements of the State Board of Pharmacy to reflect contemporary workforce and professional considerations.

Key Provisions and Changes

Amends the act that governs the State Board of Pharmacy (the board responsible for licensure, regulation, and discipline of pharmacists and pharmacies in Pennsylvania).

The centerpiece of the bill is to modify who can serve on the State Board of Pharmacy, i.e., its membership composition. The exact changes to the number of seats, eligibility criteria, or balances among pharmacists, consumer/public members, and other professionals are not detailed in the provided summary text, but the title and memo indicate an update to membership.

Who/What Is Affected

The State Board of Pharmacy, as the licensing and regulatory authority, would be directly affected since the bill alters its membership structure.

Pharmacists, pharmacy students, pharmacy employers, and the public may experience indirect effects through potential changes in how the board governs licensure processes, disciplinary actions, scope of practice oversight, and regulatory priorities.

Other stakeholders in Pennsylvania’s healthcare community that interact with the board (e.g., pharmacies, wholesalers, and professional associations) could be affected by any changes in board operations or regulatory emphasis resulting from different membership compositions.

Procedural and Timeline Aspects

Senate Committees: Referred to the Senate Consumer Protection & Professional Licensure Committee on January 9, 2026.

Committee Action: On June 10, 2026, the committee reported the bill as amended with a favorable vote (14 yes, 0 no). An amendment (A03429) was adopted, and the bill was reported as amended with the same favorable tally.

Floor Action: The bill has had first consideration in the Senate as of June 10, 2026. It would proceed to further floor debate and voting in the Senate, and, if passed, would move to the House for consideration (not shown in the provided history).

Additional Notes

The bill is part of a broader set of Pharmacy Act amendments considered during the 2025-2026 session, alongside other pharmacy-related measures.

A “Memo Subject” accompanying the bill indicates the intent to update the membership of the State Board of Pharmacy, which aligns with the substantive change described.

Practical Implications (What to Watch)

Details of the new board makeup: number of seats, required qualifications, term lengths, and process for filling vacancies will determine how representation and governance might shift.

Potential impact on regulatory priorities: shifts in board composition could influence licensing standards, disciplinary procedures, continuing education requirements, and scope-of-practice interpretations.

Implementation timeline: once enacted, there would be a transition plan for appointing new members per the amended provisions; timing will affect how quickly governance changes take effect.

If you’d like, I can pull the exact text of the amendments (A03429) and provide a line-by-line mapping of how the membership would change.